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ABSTRACT
CD40 stimulation can synergize with interleukin (IL)–2 for antitumor responses against mouse metastatic
renal cell carcinomas, with coincident increases in tumor-specific CD8 T-cell responses and dendritic cell
numbers in both the spleen and liver. Because CD40 is present on various hematopoietic-derived cells,
endothelial cells, and some tumors themselves, this study was performed to determine whether the antitumor
effects of CD40 stimulation and IL-2 were primarily mediated by CD40 hematopoietic-derived cells. Bone
marrow chimeras were created by reconstituting lethally irradiated CD40/ recipients with bone marrow
from CD40/ or CD40/ mice. Chimeric mice were then implanted orthotopically with renal cancer cells,
followed by treatment with anti-CD40 agonist monoclonal antibodies and IL-2. Immune parameters of the
spleen and liver were assessed after therapy and correlated with antitumor responses. The antitumor effects in
the CD40/ bone marrow transplantation chimeras were almost completely abrogated after treatment, and
this shows that hematopoietically derived CD40 cells are the principal targets for CD40 stimulation in this
model. Although both spleen and liver showed reductions in CD8 T-cell and dendritic cell expansion in the
CD40/ versus CD40/ chimeras after therapy, only the liver exhibited no significant increases in either
CD8 T cells or dendritic cells after treatment. CD40 cells on hematopoietic cells are the primary target for
anti-CD40 and IL-2 therapy. The results also suggest that the immunologic events in the liver may be more
revealing that those in lymphoid organs with regard to critical events related to responses after therapy.
© 2004 American Society for Blood and Marrow Transplantation
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aNTRODUCTION
CD40 has been shown to play a critical role in
mmune development and function. It is present on a
ariety of cell types, including B cells, dendritic cells,
nd endothelial cells [1]. The ligand for CD40 is
resent on activated T cells, natural killer cells, and
latelets, and interaction with CD40 has been shown
o exert potent co-stimulatory signals [2,3]. CD40 has
lso been shown to promote differentiation and func-
ion of dendritic cells [3,4]. CD40 stimulation has
een shown to promote antitumor effects in various
odels, in part by providing a critical signal imparted a
34y CD4 cells during cross-priming of antigen-pre-
enting cells and generation of cytolytic CD8 T
ells, thus bypassing T-cell help requirements [5]. We
ave recently demonstrated that synergistic antitumor
ffects could be achieved by administering an agonist
ntibody to CD40 with interleukin (IL)–2 in mice
ith advanced metastatic renal cell carcinoma such
hat no protective effect was observed when either
gent was given singly [6]. Signiﬁcant increases in
endritic cell number in both liver and spleen, as well
s increases in tumor-speciﬁc CD8 T-cell responses
nd numbers, were observed in treated recipients [6].
T
p
d
a
o
p
m
W
a
r
l
C
m
c
a
m
p
a
t
r
m
s
p
t
m
M
M
d
e
f
c
o
A
8
T
s
i
R
r
m
m
G
d
i
(
t
I
i
t
d
[
m
t
o
s
t
m
B
c
s
C
i
w
M
s
o
1
l
i
I
C
w
G
p
c
(
u
t
i
F
[
a
w
(
o
M
c
D
i
t
H
c
c
t
S
Antitumor Effects of CD40 Antibody and IL-2
Bhe mechanism underlying the antitumor effects was
ostulated to result from CD40 stimulation of den-
ritic precursors allowing for increased differentiation
nd function. However, because CD40 is also present
n endothelial cells and the tumor itself, it is also
ossible that the antitumor effects of anti-CD40 ad-
inistration may not be directly immunomodulatory.
e therefore addressed this issue through the cre-
tion of hematopoietic chimeras by using bone mar-
ow cell (BMCs) from CD40/ mice. Mice were
ethally irradiated and then given BMCs from either
D40/ or CD40/ wild-type controls. After 3
onths, the chimeras were implanted with renal car-
inoma cells, followed by treatment with anti-CD40
nd IL-2 treatment. The results demonstrate that he-
atopoietically derived CD40 cells do indeed play a
ivotal role in the generation of antitumor responses
fter anti-CD40 and IL-2 treatment. It is interesting
o note that the most profound effects on immune
esponses were observed in the livers of treated chi-
eras; this indicates that the liver, which is a major
ite for metastatic formation, and not the spleen, is
erhaps a more sensitive readout for correlating anti-
umor effects with various parameters of immunologic
odulation.
ATERIALS AND METHODS
ice
BALB/c mice were obtained from the Animal Pro-
uction Area of the National Cancer Institute (Fred-
rick, MD). BALB/c CD40/ mice were purchased
rom Jackson Laboratories (Bar Harbor, ME). Animal
are was provided in accordance with the procedures
utlined in the Guide for the Care and Use of Laboratory
nimals (National Institutes of Health Publication no.
6-23, 1985).
umor Cell Lines
Renca is a BALB/c renal cell adenocarcinoma of
pontaneous origin that is maintained in mice by serial
n vivo passage [7].
eagents
Recombinant human IL-2 was provided by Chi-
on Corporation (Emeryville, CA). Agonist rat anti-
ouse CD40 (clone FGK115) [8] or puriﬁed rat im-
unoglobulin G (Jackson Immunoresearch, West
rove, PA) was administered (80 g intraperitoneally)
aily, 5 times per week for 2 weeks, for a total of 10
njections; IL-2 was given in twice-daily injections
300000 IU intraperitoneally) 2 times a week for a
otal of 8 injections.
n Vivo Tumor Models
One hundred thousand Renca cells were injected
nto the left kidney of BALB/c mice. The primary m
B&MTumor was removed by unilateral nephrectomy 11
ays after tumor cell injection, as previously described
7]. To alleviate pain, mice received acetaminophen 1
g/mL in water ad libitum for 3 days after nephrec-
omy. Treatment was initiated the day after resection
f the primary tumor. Some mice were rechallenged
ubcutaneously with 105 Renca cells by injection into
he ﬂank. Survival was evaluated by using 10 to 13
ice per group. Experiments were repeated 3 times.
one Marrow Chimeras
BALB/c mice (CD40/) were irradiated with 800
Gy of total body irradiation from a cesium 137
ource. Recipients were given 10 million CD40/ or
D40/ BMCs. Cells were infused by caudal vein
njection in a 0.2-mL volume. Mice were 8 to 10
eeks old at the time of bone marrow transplantation.
ice were rested for 3 months before use in tumor
tudies. The lack of CD40 expression on spleen cells
f CD40/ bone marrow recipients was conﬁrmed at
month after transplantation and in randomly se-
ected tumor-bearing mice (3 mice per group) after
mmunotherapy.
solation of Spleen and Liver Cells
Spleens were disrupted with a stomacher (Tekmar,
incinnati, OH), and red blood cells were removed
ith ACK lysing buffer (Quality Biological, Inc.,
aithersburg, MD). Perfused livers were disrupted as
reviously described [9] by using a stomacher, and the
ell pellet was suspended in 10 mL of 40% Percoll
Pharmacia Fine Chemicals, Uppsala, Sweden) and
nderlayered with 10 mL of 80% Percoll. After cen-
rifugation at 1000g for 20 minutes, the cells at the
nterface were collected, washed, and counted.
low Cytometric Analysis
Leukocytes were labeled as previously described
6]. Brieﬂy, 106 spleen cells were labeled with primary
ntibody. Cells stained with biotinylated antibodies
ere then incubated with streptavidin-RED670
Gibco BRL, Rockville, MD). Samples were analyzed
n a FACScan ﬂow cytometer (Becton Dickinson,
ountain View, CA). Biotinylated anti-CD8 mono-
lonal antibody (clone 53-6.7; BD PharMingen, San
iego, CA)–labeled cells in the lymphocyte gate were
dentiﬁed as CD8 T cells. Dendritic cells were iden-
iﬁed with monoclonal antibodies to CD11c (clone
L3; BD PharMingen) and major histocompatibility
omplex (MHC) class II (clone AMS-321). Nonspe-
iﬁc binding was corrected with isotype-matched con-
rols.
tatistical Analysis
Survival data were plotted by the Kaplan-Meier
ethod and analyzed by the log-rank test. Compari-
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5ons of cell populations were made with the 2-tailed
tudent t test. A P value of .05 was considered
igniﬁcant.
ESULTS
ntitumor Responses after CD40 Stimulation and
L-2 in CD40/ and CD40/ Bone Marrow
himeras
Using an orthotopic model of renal cancer,
ALB/c recipients were given Renca tumor cells in-
rarenally. After 10 days, during which the tumor had
etastasized to the liver and lung, the primary tumor
as surgically removed, and the remaining metastases
ere treated with anti-CD40 and IL-2 (schema pre-
ented in Figure 1). Only the combination of anti-
D40 and IL-2 resulted in signiﬁcant increases in
urvival [6]. However, CD40 is present on a variety of
ell types [10], including the Renca tumor itself [6].
o ascertain the mechanism by which the antibody to
D40 is acting, hematopoietic BMC chimeras were
reated by using BMC from CD40/ or CD40/
ice. Congenic recipients were lethally irradiated and
nfused with BMC from CD40/ and wild-type
D40 mice. After 3 months, the extent of CD40/
r CD40/ repopulation in the chimeras was as-
essed. Chimeras receiving BMC from CD40/ do-
ors had an almost complete absence of CD40 cells
n their spleens when compared with chimeras receiv-
ng BMC from control donors (Figure 2). Dendritic
ells (CDIIc/MHC class II) were then isolated
rom the spleens of control and knockout chimeras,
nd the vast majority of the dendritic cells were neg-
tive for CD40 expression, indicating that this com-
artment was also of donor origin in these chimeras.
hus, the immune cells in the CD40 knockout chi-
eras were signiﬁcantly lacking in CD40 expression,
ndicating that the hematopoietically derived cells
ere CD40/.
The chimeras were then assessed for their abil-
ty to respond to anti-CD40 and IL-2 administra-
ion given after tumor challenge. With the sameaFigure 1. Renca orthotopic tumor model and treatment schema.
36odel as that described in Figure 1, mice were
njected with Renca cells and, after nephrectomy,
ere treated with the same regimen of anti-CD40
nd IL-2. The results demonstrate a signiﬁcant loss
P  .0001) of antitumor efﬁcacy in the CD40/
himeras when compared with the wild-type chime-
as after anti-CD40 and IL-2 administration (Fig-
re 3). It is interesting to note that a small but
tatistically signiﬁcant (P  .0005) increase in sur-
ival was observed in the CD40/ chimeras after
reatment, suggesting that CD40 on either the tu-
or or residual host cells could be a beneﬁcial
arget for the treatment regimen and that stimula-
ion of CD40 on nonhematopoietic cells could pro-
ide some protection. However, all of these recipi-
nts eventually succumbed to the tumor, whereas
0% of the control chimeras remained tumor free
fter treatment. These results demonstrate that he-
atopoietic-derived CD40 cells are responsible
or the vast majority of the therapeutic effects after
igure 2. CD40 expression in BMC chimeras. A, One month
fter bone marrow transplantation, 2 mice from CD40/ or
D40/ bone marrow chimeras were analyzed for CD40 ex-
ression on spleen cells to conﬁrm the absence of CD40 in
D40/ bone marrow chimeras. Representative histograms
rom 1 experiment are presented. B, Three mice from CD40/
r CD40/ bone marrow chimeras were analyzed for CD40
xpression on spleen cells to conﬁrm the absence of CD40 in the
endritic cell population (CDIIc/MHC class II) in CD40/
one marrow chimeras 2 days after immunotherapy in tumor-
earing animals. Representative histograms for CD40 expression
n CD11c MHC class II gated cell populations are presented.
O, knockout; WT, wild type.nti-CD40 and IL-2 administration.
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Antitumor Effects of CD40 Antibody and IL-2
Bffects of Anti-CD40 and IL-2 on Immunologic
arameters in the Spleen and Liver of Chimeric
ice
Because the antitumor effects of anti-CD40 and
L-2 could be correlated with signiﬁcant increases in
endritic cells, as well as CD8 T cells in the livers and
pleens of the tumor-bearing mice [6], we next assessed
he immunologic effects of the combination treatment in
he CD40/ chimeras. Dendritic cell assessment
MHC class II/CD11c cells) in both the livers and
pleens of the chimeras indicated a signiﬁcant reduction
f dendritic cell expansion in the CD40/ chimeras
fter combination therapy (Table 1).
It is interesting to note that when a cohort of the
ice was assessed for dendritic cell expansion in the
iver and spleen, it was observed that the spleen, al-
hough it was reduced, still had a signiﬁcant (P .005)
xpansion of dendritic cells, whereas the liver had no
igniﬁcant expansion of these cells after treatment
ompared with wild-type control chimeras (Table 1).
hus, the loss of therapeutic effects in the CD40/
himeras could be correlated with reductions in liver
igure 3. Antitumor effects of anti-CD40 and IL-2 on radiation
MC chimeras. CD40 chimeric mice were engineered by trans-
lanting bone marrow cells from CD40/ or CD40/ mice into
yeloablated CD40/ recipients. Mice received intrarenal injec-
ions of Renca followed 11 days later by unilateral nephrectomy and
he standard course of treatment with anti-CD40 and IL-2 (triangle
ymbols) or rat immunoglobulin G and vehicle controls (square
ymbols) for 12 days (as described in Materials and Methods; n 13
ice per group). CD40/ bone marrow chimeras (Œ) that received
nti-CD40 and IL-2 therapy, but not CD40/ bone marrow chi-
eras that received control injections () or CD40/ bone mar-
ow chimeras (open symbols), responded with a signiﬁcant increase
n survival (log-rank test; P .005). The results are the combination
f 2 independent experiments. KO, knockout; WT, wild type; Ig,
mmunoglobulin.endritic cells. The modest increases in dendritic cell a
B&MTumbers in the spleens of the knockout chimeras
ould be due to residual host CD40/ dendritic cells
r the effects of CD40 stimulation on the tumor itself.
hen the splenic dendritic cells were examined for
D40 expression, the cells from the CD40/ chime-
as were almost completely devoid of CD40 den-
ritic cells, again demonstrating the absence of these
ells in these BMC chimeras, even after anti-CD40
nd IL-2 treatment (Figure 4).
We then assessed the T-cell expansion that had
een documented to occur after anti-CD40 and IL-2
dministration. Splenic increases in CD8, but not
D4, T cells occurred in the tumor-bearing chime-
as after anti-CD40 and IL-2 administration. The
xtent of expansion of the CD8 T cells in the
D40/ and CD40/ chimeras was not statistically
ifferent (Table 1). No effects on CD4 T-cell ex-
ansion were observed, and this is consistent with data
howing no loss of antitumor activity in CD4 knock-
ut mice [6].
When the T-cell content of the livers was as-
essed, there was a signiﬁcant reduction in CD8 T
ells in the livers of the CD40/mice compared with
ild-type chimeras. In contrast, in the spleen, there
as a signiﬁcant increase (P  .005) in CD8 T cells
n the CD40/ chimeras (Table 1). Again, no effects
n CD4 T-cell expansion were observed in either
he CD40/ or the CD40/ chimeras, thus con-
rming the lack of effect of anti-CD40 and IL-2 on
his T-cell population. The effects of anti-CD40 and
L-2 on CD8 T-cell expansion in the livers and
pleens of CD40/ and CD40/ chimeras mirror
he data seen with dendritic cell expansion in that the
iver showed a complete absence of effects in the
D40/ chimeras. These results thus suggest that
he loss of antitumor efﬁcacy in CD40/ chimeras
ould be correlated with a reduction in immunologic
ffects, and the most signiﬁcant reductions occurred
n the liver.
ISCUSSION
Single-agent treatment modalities in cancer ther-
py often fail, particularly when given for advanced
isease. It has been previously reported that CD40
timulation can result in signiﬁcant antitumor effects
n various murine models [11-13]. IL-2 has also been
hown to exert antitumor effects in both preclinical
odels and clinical trials [14-18]. We have reported
hat the combination of anti-CD40 and IL-2 can re-
ult in synergistic antitumor effects in advanced-dis-
ase models in which neither agent alone resulted in
rotection [6]. We showed that the mechanism for
ollaboration between CD40 stimulation and IL-2
as dependent on interferon- and CD8T cells. We
lso showed that the combination, but neither agent
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5lone, increased the frequency of CD8 tumor-re-
ponsive interferon-–producing cells [6]. We specu-
ated that this occurred through the coordinate acti-
ation of both the innate and adaptive arms of the
mmune system, because both dendritic cell and tu-
or-speciﬁc CD8T cells were found to be expanded
fter combination treatment [6]. In addition, the pres-
nce of CD40 on the tumor was not required for these
ffects to occur [6]. The precise mechanism underly-
ng these antitumor effects remained unclear, how-
ver, because of the presence of CD40 on numerous
ell types (including endothelial cells) as well as on the
umor itself. The creation of radiation chimeras in
hich BMCs from CD40/ mice were used allowed
s to delineate the role of hematopoietically derived
D40 cells on the generation of antitumor effects
igure 4. Effect of anti-CD40 and IL-2 on CD40 splenic den-
ritic cell expansion in radiation BMC chimeras. Splenic dendritic
ells were identiﬁed by MHC class II and CD11c coexpression.
D40 expression was determined for this population of cells from
D40/ and CD40/ bone marrow chimeras that received either
at immunoglobulin G and vehicle control or anti-CD40 and IL-2.
O, knockout; WT, wild type; Ig, immunoglobulin.
able 1. Effect of Anti-CD40 and IL-2 on Dendritic and T-Cell Expa
Chimera Treatment Group
CD11c MHC II
Organ (1
Liver
T-WT Rat IgG  vehicle control 3.7  1.4*
T-WT Anti-CD40  rhIL-2 30.1  6.8† 5
O-WT Rat IgG  vehicle control 3.4  0.5
O-WT Anti-CD40  rhIL-2 7.7  2.4‡ 2
D40/ (WT-WT) and CD40/ (KO-WT) bone marrow ch
described in Figure 1 and Materials and Methods. Spleen cells
treatment group were pooled and analyzed for the number of d
are a combination of 2 independent experiments.
T indicates wild type; KO, knockout; Ig, immunoglobulin; rhIL
Mean  SEM; n  5.
Student t test (P  .01, compared with WT-WT rat IgG  vehic
Student t test (P  .01 compared with WT-WT anti-CD40  rh
Student t test (P  .05 compared with KO-WT rat IgG  vehicles
38fter anti-CD40 and IL-2 administration. The results
ndicated that a signiﬁcant, although not complete,
oss of antitumor activity resulted in the CD40/
himeras. The presence of modest antitumor effects in
he chimeras in the complete absence of CD40 he-
atopoietic-derived cells suggests that CD40 on the
umor itself may be responsible for at least some
mmunologic effects after CD40 stimulation. Indeed,
reliminary experiments suggest that CD40 stimula-
ion of the tumor itself can result in cytokine and
hemokine production, which may exert immunologic
ffects (L. Shorts et al., unpublished data). In addition,
L-2 has activity in both CD40 and CD40/ chi-
eras and could amplify these nonhematopoietic tar-
eted actions of anti-CD40 stimulation. However, the
ast majority of protection seen by the combination
reatment is lost in the absence of CD40 on hemato-
oietic-derived cells; this is in agreement with our
revious data, which demonstrated that CD40 tu-
or-bearing recipients could still generate synergistic
ntitumor responses [6]. It will be of interest to de-
ermine the precise nature of the cell types that re-
pond to anti-CD40 through the use of cell-speciﬁc
D40 knockout mice—in particular, ones that affect
endritic cells. It will also be of interest to determine
o what extent that the tumor can affect immunologic
esponses to CD40 stimulation and whether this can
e augmented.
The loss of antitumor activity could also be cor-
elated with the loss of immunologic expansion ob-
erved in both the livers and spleens of the chimeras.
he absence of any CD40 dendritic cells in the
pleens of the CD40/ chimeras conﬁrms the ab-
ence of CD40 in the hematopoietic-derived cells in
hese mice even after immunostimulation with anti-
D40 and IL-2. It is perhaps most interesting that the
ivers of the CD40/ chimeras had a complete ab-

Liver and Spleens of Tumor-Bearing Radiation BMC Chimeras
er CD3 CD4 T cells
per Organ (105)
CD3 CD8 T cells per
Organ (105)
n Liver Spleen Liver Spleen
9 5.8  2.1 76  36 2.9  0.6 27  6
1† 6.5  3.0 62  27 15.9  3.1† 58  8†
7 6.4  2.8 72  31 2.7  0.4 40  5
6‡§ 9.7  4.0 84  45 4.7  1.3‡ 54  1§
received rat IgG and vehicle control or anti-CD40 and IL-2 as
ht-density mononuclear cells from the liver from 2 to 3 mice per
and T cells 3 days after the completion of treatment. The results
binant human interleukin.
rol group).
atment group).
ol group).nsion in
Cells p
04)
Splee
62  1
07  5
65  1
05  3
imeras
and lig
endritic
, recom
le cont
II-2 treence of dendritic cell and CD8 T-cell expansion,
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Antitumor Effects of CD40 Antibody and IL-2
Bhereas the spleen still had a modest effect in both cell
ypes. Thus, the potential immune augmentation in
esponse to CD40 stimulation by the tumor itself in
onjunction with IL-2 administration resulted in
light, but signiﬁcant, immunomodulation that af-
ected both dendritic cells and CD8 T cells.
The spleen is heavily used in murine tumor studies
o monitor immunologic effects, much like the pe-
ipheral blood is used in clinical trials. It is becoming
ncreasingly apparent that perhaps this may not be the
ost relevant tissue in which to assess the efﬁcacy of
mmunotherapeutic approaches, because most of the
umor burden is present in other tissues, which would
e expected to be the critical site for interaction be-
ween immune cells and the tumor. Our studies con-
rm that the most signiﬁcant loss of immunomodula-
ory activities in CD40/ chimeras was detected in
he liver, which is a major site of metastasis by Renca
rom an orthotopic implant.
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